KIN-219 shows promise for treating oral mucositis and inflammatory bowel disease. In animal studies, KIN-219, a small molecule mimetic of antimicrobial peptides, reduced severe oral mucositis by over 90% and reduced severity of colitis. Kinnear Pharmaceuticals is developing KIN-219 as a rinse for oral mucositis and as a drug for IBD, with plans to conduct preclinical and clinical trials over the next 3 years. If successful, KIN-219 could generate over $500 million annually in sales and help address significant unmet needs in oncology supportive care and gastrointestinal diseases.
This document summarizes several research grant proposals awarded by the International Centre for Genetic Engineering and Biotechnology (ICGEB) in 2019. The proposals cover a wide range of topics related to agriculture, health and biotechnology:
1) A proposal to study ferroptosis-like cell death in plants which occurs in response to heat stress and could lead to new approaches for crop protection during climate change.
2) Engineering vitamin A-rich orange eggplant which could help reduce vitamin A deficiency in developing countries.
3) Defining the soybean leaf microbiome to search for disease-suppressing bacteria against Asian Soybean Rust, a major threat to Brazilian soybean production.
4) Develop
The document describes malaria immunology and epidemiology studies conducted in Papua New Guinea between 2004-2017. It involved several cohort and intervention studies with observational cohorts of approximately 500-2000 individuals. The studies aimed to understand immunity targets and mechanisms to malaria in order to rationalize vaccine development. They examined both antibody and cellular immune responses. Key findings included that γδ T cells are a major source of IFNγ response and certain NK cell receptors are associated with risk of high density infections.
OS20 POSTER - ASSESSMENT OF POTENCY AND EFFECTIVENESS OF HEPTA-VALENT FMD VAC...EuFMD
1. The study assessed the potency and effectiveness of an oil-adjuvanted heptavalent foot-and-mouth disease (FMD) vaccine containing 7 virus strains in Egypt.
2. Calves vaccinated with the vaccine were completely protected against challenge from 3 FMD virus serotypes compared to unvaccinated controls.
3. Vaccinated adult dairy cattle developed protective antibody levels against all 7 serotypes, demonstrating the vaccine's ability to induce a strong immune response under field conditions in Egypt.
- Oral insulin capsules developed by Oramed Pharmaceuticals were found to successfully lower blood sugar levels in human clinical trials. The company is now conducting a larger 90-day study to further evaluate the capsules' effects on HbA1c and their potential as a safer, more convenient alternative to injected insulin.
- Scientists at the John Innes Centre identified the last missing genes in the Madagascar periwinkle plant that allow it to produce the important cancer-fighting alkaloids vinblastine and vincristine. Understanding these genes could help increase sustainable production of these drugs through plant or synthetic biology techniques.
- Researchers at multiple institutions reported developments that could help advance cancer treatment, including
Recent advances in African swine fever vaccine development at the Internation...ILRI
Presentation by Lucilla Steinaa at a Global African Swine Fever Research Alliance (GARA)/International Alliance for Biological Standardization (IABS) webinar on current efforts in African swine fever vaccines, 6 May 2021
This document summarizes a study examining the use of biodegradable nanoparticles loaded with TGF-β and IL-2 cytokines and targeted to CD4+ cells for inducing and maintaining regulatory T cells (Tregs). The nanoparticles were able to induce CD4+ Tregs in vitro and expand their numbers in vivo. Nanoparticle-induced Tregs demonstrated enhanced stability and retained their suppressive phenotype even in inflammatory conditions, highlighting the potential of this nanoparticle approach for stabilizing Tregs to treat autoimmune disease and inflammation.
This document summarizes several research grant proposals awarded by the International Centre for Genetic Engineering and Biotechnology (ICGEB) in 2019. The proposals cover a wide range of topics related to agriculture, health and biotechnology:
1) A proposal to study ferroptosis-like cell death in plants which occurs in response to heat stress and could lead to new approaches for crop protection during climate change.
2) Engineering vitamin A-rich orange eggplant which could help reduce vitamin A deficiency in developing countries.
3) Defining the soybean leaf microbiome to search for disease-suppressing bacteria against Asian Soybean Rust, a major threat to Brazilian soybean production.
4) Develop
The document describes malaria immunology and epidemiology studies conducted in Papua New Guinea between 2004-2017. It involved several cohort and intervention studies with observational cohorts of approximately 500-2000 individuals. The studies aimed to understand immunity targets and mechanisms to malaria in order to rationalize vaccine development. They examined both antibody and cellular immune responses. Key findings included that γδ T cells are a major source of IFNγ response and certain NK cell receptors are associated with risk of high density infections.
OS20 POSTER - ASSESSMENT OF POTENCY AND EFFECTIVENESS OF HEPTA-VALENT FMD VAC...EuFMD
1. The study assessed the potency and effectiveness of an oil-adjuvanted heptavalent foot-and-mouth disease (FMD) vaccine containing 7 virus strains in Egypt.
2. Calves vaccinated with the vaccine were completely protected against challenge from 3 FMD virus serotypes compared to unvaccinated controls.
3. Vaccinated adult dairy cattle developed protective antibody levels against all 7 serotypes, demonstrating the vaccine's ability to induce a strong immune response under field conditions in Egypt.
- Oral insulin capsules developed by Oramed Pharmaceuticals were found to successfully lower blood sugar levels in human clinical trials. The company is now conducting a larger 90-day study to further evaluate the capsules' effects on HbA1c and their potential as a safer, more convenient alternative to injected insulin.
- Scientists at the John Innes Centre identified the last missing genes in the Madagascar periwinkle plant that allow it to produce the important cancer-fighting alkaloids vinblastine and vincristine. Understanding these genes could help increase sustainable production of these drugs through plant or synthetic biology techniques.
- Researchers at multiple institutions reported developments that could help advance cancer treatment, including
Recent advances in African swine fever vaccine development at the Internation...ILRI
Presentation by Lucilla Steinaa at a Global African Swine Fever Research Alliance (GARA)/International Alliance for Biological Standardization (IABS) webinar on current efforts in African swine fever vaccines, 6 May 2021
This document summarizes a study examining the use of biodegradable nanoparticles loaded with TGF-β and IL-2 cytokines and targeted to CD4+ cells for inducing and maintaining regulatory T cells (Tregs). The nanoparticles were able to induce CD4+ Tregs in vitro and expand their numbers in vivo. Nanoparticle-induced Tregs demonstrated enhanced stability and retained their suppressive phenotype even in inflammatory conditions, highlighting the potential of this nanoparticle approach for stabilizing Tregs to treat autoimmune disease and inflammation.
CORRELATION BETWEEN SEROLOGICAL TITER AND PROTECTION IN PIGS VACCINATED WITH ...EuFMD
This academic research poster summarizes a study analyzing the correlation between vaccination antibody titers (VNTs) and protection against foot-and-mouth disease virus (FMDV) in pigs. The study used data from 112 vaccinated pigs challenged with FMDV. Statistical analysis showed a close correlation between VNT levels at 28 days post-vaccination and protection, with a VNT of 0.9 associated with at least 75% protection. In contrast, VNT levels at other time points showed less correlation with protection. These results suggest VNT levels can predict vaccine protection in pigs and support using serology for FMD control. However, more research is needed to validate this approach for other FMDV subtypes and
In this SlideShare, we're covering an overview on RNA technologies and recent applications in the field of life sciences. RNA is the pivotal ‘molecule of life’, involved in almost all aspects of cell biology. Recent successes in mRNA-based vaccines indicate just one of the near-infinite possibilities that RNA technology can offer in life sciences.
Advances in immunotherapy for lymphomas and myelomasspa718
This document summarizes advances in cancer immunotherapy for lymphomas and myelomas. It describes positive phase III clinical trials of cancer vaccines for prostate cancer, melanoma, and lymphoma that were FDA approved. It then focuses on the development of an idiotype vaccine for B-cell lymphomas from an academic laboratory through preclinical and clinical trials, including a positive phase III trial showing improved disease-free survival. Future directions discussed include combining the idiotype vaccine with other therapies like anti-CD20 antibodies or adoptive T-cell therapies. The development of second-generation DNA idiotype vaccines to improve manufacturing is also presented.
Candidemia in HIV-positive patients in Dschang District Hospital (West Region...Claude Nangwat
Candidemia has been identified as a public health problem in HIV-infected patients. The evaluation of CD4 count, transaminases and blood glucose, are being used as a means to monitor the health of HIV-infected patients, without excluding the diagnosis of candidemia and other opportunistic infections. In order to contribute in improving the care of HIV-infected patients attending Dschang District Hospital and later on, in other hospitals in Cameroon, we conducted from June to September 2014 a cross-sectional study, with general objective; to determine the association between candidemia and selected biochemical and haematological parameter changes in HIV-infected patients, as a possible indicator in monitoring HIV disease progression.
To do this, blood samples were collected from HIV-infected patients assigned to the UPEC of Dschang District Hospital for follow up, and haemogram report, CD4 counts, ALAT level, ASAT level, and glucose level in blood were evaluated by cytometric and spectrophotometric assays. Candida species were isolated from some blood samples, and then identified using CHROMagar Candida culture medium. The broth microdilution method was afterwards used to test the susceptibility of the fungal isolates vis-a-vis three conventional antifungal agents.
Mycological analysis of blood samples showed that eight (08) patients had candidemia, a prevalence of 6.11%. Eight (08) isolates were obtained from these eight (08) candidemic HIV-infected patients; this consisted of 4(50%) Candida albicans, 3(37.5%) Candida parapsilosis and 1(12.5%) Candida glabrata. All these isolates were resistant (MICs ranged from 2 to >256 µg/mL) to the antifungals used, that is, ketoconazole, amphotericin B and nystatin.
A significant correlation was found between candidemia and white blood cell count, with a correlation coefficient of r = 0.240 (p < 0.05). Based on the results obtained, the systematic diagnosis of candidemia should be performed in patients infected with HIV in Cameroon in order to improve on their care.
Key words: Candidemia, HIV, biochemical parameters, hematological parameters, Antifungals activities.
- ImmunoScience is a life sciences company focused on immunology, specifically novel cancer and HIV therapies
- For cancer, they are developing a therapeutic vaccine using a DNA virus vector containing markers for multiple cancers that aims to generate a robust immune response
- For HIV, they are developing a live-attenuated therapeutic vaccine called Contre Vir that harnesses the immune system to cure HIV infection by removing the nef gene, which helps HIV evade immune detection
- Early pilot studies of Contre Vir showed improved CD4 counts and viral load reductions, though larger studies are still needed to prove efficacy
1) The study investigated how Gram-negative bacterial lipopolysaccharide (LPS), a component of bacteria like Chlamydia and Neisseria that cause STIs, affects expression of HIV receptors in cervical epithelial cells.
2) The results showed that LPS increased expression of the CCR5 HIV co-receptor and other alternative receptors in cervical cells through activation of EGFR, ERK1/2, and COX-2 signaling pathways.
3) This suggests that STIs have the potential to enhance susceptibility to HIV infection in women by regulating expression of HIV receptors in cervical epithelial cells through an inflammatory response.
This document summarizes research on genome editing in poultry. It discusses how gene editing could help address issues like disease resilience and food allergies in chickens. The researchers have used CRISPR-Cas9 to successfully edit genes in chicken primordial germ cells (PGCs) through direct injection. This led to heterozygous and homozygous gene deletions being passed down to subsequent generations. Applications mentioned include deleting allergenic proteins from eggs and improving resistance to avian influenza. The document acknowledges the team conducting this research and expresses hope that their work can enhance sustainability, health, and efficiency in poultry production while improving food safety.
An integrated genomic surveillance platform reveals multiple introductions an...Data Con LA
Data Con LA 2020
Description
The Children's Hospital, Los Angeles (CHLA) COVID-19 Analysis Research Database (CARD) (https://covid19.cpmbiodev.net/) is a comprehensive genomic resource of SARS-CoV-2 viral genomes and associated meta-data of over 80,000 (as of August 13, 2020) isolates collected from global sequencing laboratories and the Center for Personalized Medicine (CPM) at CHLA. A Virus Genome Tracker accepts virus genome sequence and places the new viral isolate within the global or USA phylogenetic contexts based upon variant and haplotype comparisons to trace the transmission for genomic surveillance.
By haplotype analysis of 4,200 California isolates, 6,356 USA isolates, and over 80,000 global isolates, we identified a pattern of strongly localized outbreaks at the city-, state-, and country-levels, and temporal transmissions. Phylogenetic analyses revealed the cryptic introduction of multiple SARS-CoV-2 lineages into California and Los Angeles, deriving from state-to-state transmission, and from international travel by air and ship. The majority of sequences Orange County isolates formed distinct outbreak clusters whose haplotypes were different from isolates of the neighboring Los Angeles. From the 50,000 global isolates, 22,171 (45.8%) isolates carried country-private haplotypes. The percentage were 28.2-29.6% in January to March, and rapidly increased to 46.4% and 59.6% in April and May, co-occurring with global travel restrictions.
Speaker
Lishuang Shen, Children's Hospital Los Angeles, Sr. Bioinformatics Scientist
1.72±0.25
1.88±0.35
1.72±0.15
15.01±10.50
17.01±24.16
20.07±1.57
21.12±8.41
23.01±1.12
25.12±5.56
27.21±25.37
28.88±0.97
33.94±0.97
The study examined the immune response to the hepatitis B virus vaccine in vaccinated groups. ELISA assays were used to detect hepatitis B surface antigen and antibodies in serum samples before and after vaccination.
Effect of the Gayatri Mantra Playing on Microbial Load in Room AirBhoj Raj Singh
In the study, the effect of the Gayatri Mantra playing for 24 hr on microbial quality of air was examined in 12 rooms of scientists of the ICAR-Indian Veterinary Research Institute, Izatnagar, India willing to participate in the study and in 7 empty classroom/ examination hall lying vacant since March 2020 due to COVID-19. Of the empty rooms, 6 were used as the control for the first two days, then after a week, all rooms were also used to detect the effect of playing the Gayatri Mantra. A total of 31 bacterial species of medical importance were isolated and identified in the air of the rooms. After playing the Gayatri Mantra in Raag Bhairvi for 24 h bacterial count significantly decreased in rooms inhabited by vegetarian (OR 24, CI 95: 0.00-0.88; p, 0.036) than in rooms occupied by non-vegetarians. Rooms occupied by vegetarians. The effect of Gayatri Mantra in the empty room had no significant difference but bacterial count reduced. Bacterial counts of rooms occupied by non-vegetarian increased significantly post Mantra playing. Bacterial counts of rooms occupied by non-vegetarians and empty rooms varied significantly (OR 18, p, 0.02, CI 95: 0.00 – 0.79). Empty rooms with and without mantra not varied significantly for the reduction of the bacterial count. Paenibacillus spp. was not detected in any of the 12 rooms occupied by the scientists/ staff but in 3 of the 7 empty rooms (p, 0.01) it was detected even without playing any mantra. It indicated that daily disturbance in the environment may be detrimental to the survival of Paenibacillus spp. After playing Mantra P. alvei, P. cookie, P. lautus were detected in 5 of the seven rooms occupied by Non-vegetarians, while P. pantothenicus continued to be present in three of the vacant rooms even after playing the Mantra. Paenibacillus spp. bacteria are known for their probiotic potential and its significance in the study is not clear. It seems that the Gayatri mantra has some enrichment effect on Paenibacillus spp. but a detrimental effect on other microbes.
Evaluation Of Acinetobacter Infection, Eastern States Presentationnels1937
The document summarizes a study evaluating treatment outcomes for Acinetobacter infections at a hospital. 112 patients with Acinetobacter infections were included in the retrospective study. Appropriate empiric and tailored antimicrobial therapy were associated with favorable outcomes. Common treatments included imipenem, colistin, tigecycline, and piperacillin/tazobactam. Colistin was effective against multi-drug resistant strains but caused increased creatinine and BUN levels in some patients. Selection of correct empiric therapy was found to be important for treatment success.
Challenges of using phages in the veterinary world: My learning curveILRI
This document summarizes Arshnee Moodley's experiences using bacteriophages to treat veterinary infections. Some key points:
- She isolated phages against methicillin-resistant Staphylococcus pseudintermedius (MRSP) from dog feces but they were temperate and not suitable for therapy. She tested a PlySS2 lysin against MRSP with success in vitro.
- She treated a dog with chronic Pseudomonas aeruginosa otitis externa using a single phage that showed a 1-2 log reduction over 6 days and improved clinical outcomes.
- Her work on developing phage lysins against MRSP included expression challenges with one lysin and successful
Mutant prevention concentrations of some aminoglycoside antibiotics for fecal...Alexander Decker
This document reports on a study that evaluated the mutant prevention concentrations (MPCs) of three aminoglycoside antibiotics (streptomycin, gentamicin, and amikacin) against fecal isolates of Escherichia coli at different growth temperatures. Fifty E. coli isolates from patient stool samples were tested for antibiotic minimum inhibitory concentrations and MPCs at 37°C and 41°C. For each antibiotic, the MPC50 and MPC90 values and MPC/MIC ratios were the same at both temperatures tested. Higher numbers of resistant mutants were recovered at the MPCs for isolates at 41°C compared to 37°C, indicating that higher temperatures favor the selection of resistant mutants. The M
Marios Stylianou_Paper III_Antifungal application of nonantifungal drugs.Marios Stylianou
This study screened 844 drugs from two libraries against Candida albicans to identify previously unknown antifungal activities. 26 drugs showed antifungal activity, including 12 standard antifungal drugs and 7 drugs previously reported to have anti-Candida activity. The screening identified 7 additional drugs with antifungal activity: amonafide, tosedostat, megestrol acetate, melengestrol acetate, stanozolol, trifluperidol, and haloperidol. Further analysis found these 7 drugs had antifungal activity comparable to the standard antifungal drugs against multiple Candida species. The aminopeptidase inhibitor tosedostat displayed broad antifungal activity, including against Candid
This research article describes a novel method using high-density peptide microarrays and computational analysis to identify B-cell epitopes in patients with celiac disease. Overlapping peptide sequences from native and deamidated gliadin proteins were synthesized onto silicon wafers. Serum samples from celiac patients and controls were tested on the microarrays. Computational analysis identified distinct epitope sets that differentiated celiac patients from controls with high accuracy. The identified epitopes have potential for developing improved diagnostic tests for celiac disease.
This presentation discusses the intersection of biotechnology and medical science. It explains that biotechnology involves using living organisms to develop useful products, and has advanced areas like drug development, nutrition, agriculture, and environmental protection. Medicine involves diagnosing and treating disease. The presentation then outlines how biotechnology has contributed to improvements in medicine, including producing drugs and therapeutics through genetic engineering, enabling more accurate disease diagnosis and detection of genetic predispositions, and facilitating gene therapy, pharmacogenomics, genetic testing, and targeted drug delivery. Specific biotechnology applications in medicine discussed include monoclonal antibodies, DNA probes, and vaccines.
1) The peptide antimicrobials retrocyclin (RC-100) and protegrin-1 (PG-1) were found to activate human mast cells by inducing calcium mobilization and degranulation.
2) While RC-100 and PG-1 activated mast cells, only PG-1 displayed antimicrobial activity against bacteria, suggesting dissociation between mast cell activation and antimicrobial function for RC-100.
3) Mast cell activation by RC-100 and PG-1 occurred independently of the formyl peptide receptor FPRL1 but likely through the G protein coupled receptor MrgX2, similarly to other antimicrobial peptides.
This document summarizes Dr. Hui-Wen Chen's presentation on nanovaccine research and industry-academia collaboration experiences. It discusses her lab's development of nanoparticle vaccines for MERS-CoV, influenza, and cancer which showed strong antibody and T cell immune responses in animal studies. Her lab is currently working on COVID-19 RBD and T cell vaccines. The document also notes some challenges faced, including changes in research directions, funding issues, and market saturation concerns from industry partners.
The document summarizes a report on medicine use and shifting healthcare costs in the United States in 2013. Key findings include:
- Healthcare and medicine utilization increased in 2013 as patient office visits rebounded after years of decline, while emergency room visits slowed. Prescriptions per capita also rose slightly.
- Out-of-pocket costs for patients continue to rise due to higher deductibles and co-payments, though most prescriptions cost $10 or less. Variations exist between insurance types.
- 36 new drugs were launched in 2013, including treatments for cancer, hepatitis C, and other diseases, transforming care for many conditions.
This document summarizes market research findings on Ensure and Pediasure in various areas of Egypt. It finds that Ensure holds 70% of the market share compared to competitors Growth Formula at 20% and Biogainers at 10%. While Ensure is number one in Faisal, Haram, 6 October and Mohandiseen, it is number two to Biogainers in Dokki and Giza. Key prescribers of each product are identified. The document recommends increasing promotion of Ensure to doctors and pharmacists and making samples available to gain prescribers and market share.
CORRELATION BETWEEN SEROLOGICAL TITER AND PROTECTION IN PIGS VACCINATED WITH ...EuFMD
This academic research poster summarizes a study analyzing the correlation between vaccination antibody titers (VNTs) and protection against foot-and-mouth disease virus (FMDV) in pigs. The study used data from 112 vaccinated pigs challenged with FMDV. Statistical analysis showed a close correlation between VNT levels at 28 days post-vaccination and protection, with a VNT of 0.9 associated with at least 75% protection. In contrast, VNT levels at other time points showed less correlation with protection. These results suggest VNT levels can predict vaccine protection in pigs and support using serology for FMD control. However, more research is needed to validate this approach for other FMDV subtypes and
In this SlideShare, we're covering an overview on RNA technologies and recent applications in the field of life sciences. RNA is the pivotal ‘molecule of life’, involved in almost all aspects of cell biology. Recent successes in mRNA-based vaccines indicate just one of the near-infinite possibilities that RNA technology can offer in life sciences.
Advances in immunotherapy for lymphomas and myelomasspa718
This document summarizes advances in cancer immunotherapy for lymphomas and myelomas. It describes positive phase III clinical trials of cancer vaccines for prostate cancer, melanoma, and lymphoma that were FDA approved. It then focuses on the development of an idiotype vaccine for B-cell lymphomas from an academic laboratory through preclinical and clinical trials, including a positive phase III trial showing improved disease-free survival. Future directions discussed include combining the idiotype vaccine with other therapies like anti-CD20 antibodies or adoptive T-cell therapies. The development of second-generation DNA idiotype vaccines to improve manufacturing is also presented.
Candidemia in HIV-positive patients in Dschang District Hospital (West Region...Claude Nangwat
Candidemia has been identified as a public health problem in HIV-infected patients. The evaluation of CD4 count, transaminases and blood glucose, are being used as a means to monitor the health of HIV-infected patients, without excluding the diagnosis of candidemia and other opportunistic infections. In order to contribute in improving the care of HIV-infected patients attending Dschang District Hospital and later on, in other hospitals in Cameroon, we conducted from June to September 2014 a cross-sectional study, with general objective; to determine the association between candidemia and selected biochemical and haematological parameter changes in HIV-infected patients, as a possible indicator in monitoring HIV disease progression.
To do this, blood samples were collected from HIV-infected patients assigned to the UPEC of Dschang District Hospital for follow up, and haemogram report, CD4 counts, ALAT level, ASAT level, and glucose level in blood were evaluated by cytometric and spectrophotometric assays. Candida species were isolated from some blood samples, and then identified using CHROMagar Candida culture medium. The broth microdilution method was afterwards used to test the susceptibility of the fungal isolates vis-a-vis three conventional antifungal agents.
Mycological analysis of blood samples showed that eight (08) patients had candidemia, a prevalence of 6.11%. Eight (08) isolates were obtained from these eight (08) candidemic HIV-infected patients; this consisted of 4(50%) Candida albicans, 3(37.5%) Candida parapsilosis and 1(12.5%) Candida glabrata. All these isolates were resistant (MICs ranged from 2 to >256 µg/mL) to the antifungals used, that is, ketoconazole, amphotericin B and nystatin.
A significant correlation was found between candidemia and white blood cell count, with a correlation coefficient of r = 0.240 (p < 0.05). Based on the results obtained, the systematic diagnosis of candidemia should be performed in patients infected with HIV in Cameroon in order to improve on their care.
Key words: Candidemia, HIV, biochemical parameters, hematological parameters, Antifungals activities.
- ImmunoScience is a life sciences company focused on immunology, specifically novel cancer and HIV therapies
- For cancer, they are developing a therapeutic vaccine using a DNA virus vector containing markers for multiple cancers that aims to generate a robust immune response
- For HIV, they are developing a live-attenuated therapeutic vaccine called Contre Vir that harnesses the immune system to cure HIV infection by removing the nef gene, which helps HIV evade immune detection
- Early pilot studies of Contre Vir showed improved CD4 counts and viral load reductions, though larger studies are still needed to prove efficacy
1) The study investigated how Gram-negative bacterial lipopolysaccharide (LPS), a component of bacteria like Chlamydia and Neisseria that cause STIs, affects expression of HIV receptors in cervical epithelial cells.
2) The results showed that LPS increased expression of the CCR5 HIV co-receptor and other alternative receptors in cervical cells through activation of EGFR, ERK1/2, and COX-2 signaling pathways.
3) This suggests that STIs have the potential to enhance susceptibility to HIV infection in women by regulating expression of HIV receptors in cervical epithelial cells through an inflammatory response.
This document summarizes research on genome editing in poultry. It discusses how gene editing could help address issues like disease resilience and food allergies in chickens. The researchers have used CRISPR-Cas9 to successfully edit genes in chicken primordial germ cells (PGCs) through direct injection. This led to heterozygous and homozygous gene deletions being passed down to subsequent generations. Applications mentioned include deleting allergenic proteins from eggs and improving resistance to avian influenza. The document acknowledges the team conducting this research and expresses hope that their work can enhance sustainability, health, and efficiency in poultry production while improving food safety.
An integrated genomic surveillance platform reveals multiple introductions an...Data Con LA
Data Con LA 2020
Description
The Children's Hospital, Los Angeles (CHLA) COVID-19 Analysis Research Database (CARD) (https://covid19.cpmbiodev.net/) is a comprehensive genomic resource of SARS-CoV-2 viral genomes and associated meta-data of over 80,000 (as of August 13, 2020) isolates collected from global sequencing laboratories and the Center for Personalized Medicine (CPM) at CHLA. A Virus Genome Tracker accepts virus genome sequence and places the new viral isolate within the global or USA phylogenetic contexts based upon variant and haplotype comparisons to trace the transmission for genomic surveillance.
By haplotype analysis of 4,200 California isolates, 6,356 USA isolates, and over 80,000 global isolates, we identified a pattern of strongly localized outbreaks at the city-, state-, and country-levels, and temporal transmissions. Phylogenetic analyses revealed the cryptic introduction of multiple SARS-CoV-2 lineages into California and Los Angeles, deriving from state-to-state transmission, and from international travel by air and ship. The majority of sequences Orange County isolates formed distinct outbreak clusters whose haplotypes were different from isolates of the neighboring Los Angeles. From the 50,000 global isolates, 22,171 (45.8%) isolates carried country-private haplotypes. The percentage were 28.2-29.6% in January to March, and rapidly increased to 46.4% and 59.6% in April and May, co-occurring with global travel restrictions.
Speaker
Lishuang Shen, Children's Hospital Los Angeles, Sr. Bioinformatics Scientist
1.72±0.25
1.88±0.35
1.72±0.15
15.01±10.50
17.01±24.16
20.07±1.57
21.12±8.41
23.01±1.12
25.12±5.56
27.21±25.37
28.88±0.97
33.94±0.97
The study examined the immune response to the hepatitis B virus vaccine in vaccinated groups. ELISA assays were used to detect hepatitis B surface antigen and antibodies in serum samples before and after vaccination.
Effect of the Gayatri Mantra Playing on Microbial Load in Room AirBhoj Raj Singh
In the study, the effect of the Gayatri Mantra playing for 24 hr on microbial quality of air was examined in 12 rooms of scientists of the ICAR-Indian Veterinary Research Institute, Izatnagar, India willing to participate in the study and in 7 empty classroom/ examination hall lying vacant since March 2020 due to COVID-19. Of the empty rooms, 6 were used as the control for the first two days, then after a week, all rooms were also used to detect the effect of playing the Gayatri Mantra. A total of 31 bacterial species of medical importance were isolated and identified in the air of the rooms. After playing the Gayatri Mantra in Raag Bhairvi for 24 h bacterial count significantly decreased in rooms inhabited by vegetarian (OR 24, CI 95: 0.00-0.88; p, 0.036) than in rooms occupied by non-vegetarians. Rooms occupied by vegetarians. The effect of Gayatri Mantra in the empty room had no significant difference but bacterial count reduced. Bacterial counts of rooms occupied by non-vegetarian increased significantly post Mantra playing. Bacterial counts of rooms occupied by non-vegetarians and empty rooms varied significantly (OR 18, p, 0.02, CI 95: 0.00 – 0.79). Empty rooms with and without mantra not varied significantly for the reduction of the bacterial count. Paenibacillus spp. was not detected in any of the 12 rooms occupied by the scientists/ staff but in 3 of the 7 empty rooms (p, 0.01) it was detected even without playing any mantra. It indicated that daily disturbance in the environment may be detrimental to the survival of Paenibacillus spp. After playing Mantra P. alvei, P. cookie, P. lautus were detected in 5 of the seven rooms occupied by Non-vegetarians, while P. pantothenicus continued to be present in three of the vacant rooms even after playing the Mantra. Paenibacillus spp. bacteria are known for their probiotic potential and its significance in the study is not clear. It seems that the Gayatri mantra has some enrichment effect on Paenibacillus spp. but a detrimental effect on other microbes.
Evaluation Of Acinetobacter Infection, Eastern States Presentationnels1937
The document summarizes a study evaluating treatment outcomes for Acinetobacter infections at a hospital. 112 patients with Acinetobacter infections were included in the retrospective study. Appropriate empiric and tailored antimicrobial therapy were associated with favorable outcomes. Common treatments included imipenem, colistin, tigecycline, and piperacillin/tazobactam. Colistin was effective against multi-drug resistant strains but caused increased creatinine and BUN levels in some patients. Selection of correct empiric therapy was found to be important for treatment success.
Challenges of using phages in the veterinary world: My learning curveILRI
This document summarizes Arshnee Moodley's experiences using bacteriophages to treat veterinary infections. Some key points:
- She isolated phages against methicillin-resistant Staphylococcus pseudintermedius (MRSP) from dog feces but they were temperate and not suitable for therapy. She tested a PlySS2 lysin against MRSP with success in vitro.
- She treated a dog with chronic Pseudomonas aeruginosa otitis externa using a single phage that showed a 1-2 log reduction over 6 days and improved clinical outcomes.
- Her work on developing phage lysins against MRSP included expression challenges with one lysin and successful
Mutant prevention concentrations of some aminoglycoside antibiotics for fecal...Alexander Decker
This document reports on a study that evaluated the mutant prevention concentrations (MPCs) of three aminoglycoside antibiotics (streptomycin, gentamicin, and amikacin) against fecal isolates of Escherichia coli at different growth temperatures. Fifty E. coli isolates from patient stool samples were tested for antibiotic minimum inhibitory concentrations and MPCs at 37°C and 41°C. For each antibiotic, the MPC50 and MPC90 values and MPC/MIC ratios were the same at both temperatures tested. Higher numbers of resistant mutants were recovered at the MPCs for isolates at 41°C compared to 37°C, indicating that higher temperatures favor the selection of resistant mutants. The M
Marios Stylianou_Paper III_Antifungal application of nonantifungal drugs.Marios Stylianou
This study screened 844 drugs from two libraries against Candida albicans to identify previously unknown antifungal activities. 26 drugs showed antifungal activity, including 12 standard antifungal drugs and 7 drugs previously reported to have anti-Candida activity. The screening identified 7 additional drugs with antifungal activity: amonafide, tosedostat, megestrol acetate, melengestrol acetate, stanozolol, trifluperidol, and haloperidol. Further analysis found these 7 drugs had antifungal activity comparable to the standard antifungal drugs against multiple Candida species. The aminopeptidase inhibitor tosedostat displayed broad antifungal activity, including against Candid
This research article describes a novel method using high-density peptide microarrays and computational analysis to identify B-cell epitopes in patients with celiac disease. Overlapping peptide sequences from native and deamidated gliadin proteins were synthesized onto silicon wafers. Serum samples from celiac patients and controls were tested on the microarrays. Computational analysis identified distinct epitope sets that differentiated celiac patients from controls with high accuracy. The identified epitopes have potential for developing improved diagnostic tests for celiac disease.
This presentation discusses the intersection of biotechnology and medical science. It explains that biotechnology involves using living organisms to develop useful products, and has advanced areas like drug development, nutrition, agriculture, and environmental protection. Medicine involves diagnosing and treating disease. The presentation then outlines how biotechnology has contributed to improvements in medicine, including producing drugs and therapeutics through genetic engineering, enabling more accurate disease diagnosis and detection of genetic predispositions, and facilitating gene therapy, pharmacogenomics, genetic testing, and targeted drug delivery. Specific biotechnology applications in medicine discussed include monoclonal antibodies, DNA probes, and vaccines.
1) The peptide antimicrobials retrocyclin (RC-100) and protegrin-1 (PG-1) were found to activate human mast cells by inducing calcium mobilization and degranulation.
2) While RC-100 and PG-1 activated mast cells, only PG-1 displayed antimicrobial activity against bacteria, suggesting dissociation between mast cell activation and antimicrobial function for RC-100.
3) Mast cell activation by RC-100 and PG-1 occurred independently of the formyl peptide receptor FPRL1 but likely through the G protein coupled receptor MrgX2, similarly to other antimicrobial peptides.
This document summarizes Dr. Hui-Wen Chen's presentation on nanovaccine research and industry-academia collaboration experiences. It discusses her lab's development of nanoparticle vaccines for MERS-CoV, influenza, and cancer which showed strong antibody and T cell immune responses in animal studies. Her lab is currently working on COVID-19 RBD and T cell vaccines. The document also notes some challenges faced, including changes in research directions, funding issues, and market saturation concerns from industry partners.
The document summarizes a report on medicine use and shifting healthcare costs in the United States in 2013. Key findings include:
- Healthcare and medicine utilization increased in 2013 as patient office visits rebounded after years of decline, while emergency room visits slowed. Prescriptions per capita also rose slightly.
- Out-of-pocket costs for patients continue to rise due to higher deductibles and co-payments, though most prescriptions cost $10 or less. Variations exist between insurance types.
- 36 new drugs were launched in 2013, including treatments for cancer, hepatitis C, and other diseases, transforming care for many conditions.
This document summarizes market research findings on Ensure and Pediasure in various areas of Egypt. It finds that Ensure holds 70% of the market share compared to competitors Growth Formula at 20% and Biogainers at 10%. While Ensure is number one in Faisal, Haram, 6 October and Mohandiseen, it is number two to Biogainers in Dokki and Giza. Key prescribers of each product are identified. The document recommends increasing promotion of Ensure to doctors and pharmacists and making samples available to gain prescribers and market share.
The report contains the following four chapters:
Chapter 1: Global Pharmaceutical Market
Chapter 2: Solutions to Challenges
Chapter 3: Global Players
Chapter 4: Overview of Industry Trends
You may follow my blog: biostrategyanalytics.wordpress.com for further posts related to financial and strategic issues in the Pharmaceutical / Biotechnology sector.
For any questions or recommendations do not hesitate to contact me.
Study: The Future of VR, AR and Self-Driving CarsLinkedIn
We asked LinkedIn members worldwide about their levels of interest in the latest wave of technology: whether they’re using wearables, and whether they intend to buy self-driving cars and VR headsets as they become available. We asked them too about their attitudes to technology and to the growing role of Artificial Intelligence (AI) in the devices that they use. The answers were fascinating – and in many cases, surprising.
This SlideShare explores the full results of this study, including detailed market-by-market breakdowns of intention levels for each technology – and how attitudes change with age, location and seniority level. If you’re marketing a tech brand – or planning to use VR and wearables to reach a professional audience – then these are insights you won’t want to miss.
UX, ethnography and possibilities: for Libraries, Museums and ArchivesNed Potter
1) The document discusses how the University of York Library has used various user experience (UX) techniques like ethnographic observation and interviews to better understand user needs and behaviors.
2) Some changes implemented based on UX findings include installing hot water taps, changing hours, and adding blankets - aimed at improving the small details of user experience.
3) The presentation encourages other libraries, archives and museums to try incorporating UX techniques like behavioral mapping and cognitive interviews to inform design changes that enhance services for users.
Artificial intelligence (AI) is everywhere, promising self-driving cars, medical breakthroughs, and new ways of working. But how do you separate hype from reality? How can your company apply AI to solve real business problems?
Here’s what AI learnings your business should keep in mind for 2017.
The document discusses designing teams and processes to adapt to changing needs. It recommends structuring teams so members can work within their competencies and across projects fluidly with clear roles and expectations. The design process should support the team and their work, and be flexible enough to change with team, organization, and project needs. An effective team culture builds an environment where members feel free to be themselves, voice opinions, and feel supported.
An immersive workshop at General Assembly, SF. I typically teach this workshop at General Assembly, San Francisco. To see a list of my upcoming classes, visit https://generalassemb.ly/instructors/seth-familian/4813
I also teach this workshop as a private lunch-and-learn or half-day immersive session for corporate clients. To learn more about pricing and availability, please contact me at http://familian1.com
3 Things Every Sales Team Needs to Be Thinking About in 2017Drift
Thinking about your sales team's goals for 2017? Drift's VP of Sales shares 3 things you can do to improve conversion rates and drive more revenue.
Read the full story on the Drift blog here: http://blog.drift.com/sales-team-tips
TEDx Manchester: AI & The Future of WorkVolker Hirsch
TEDx Manchester talk on artificial intelligence (AI) and how the ascent of AI and robotics impacts our future work environments.
The video of the talk is now also available here: https://youtu.be/dRw4d2Si8LA
How to Become a Thought Leader in Your NicheLeslie Samuel
Are bloggers thought leaders? Here are some tips on how you can become one. Provide great value, put awesome content out there on a regular basis, and help others.
Not sure what to share on SlideShare?
SlideShares that inform, inspire and educate attract the most views. Beyond that, ideas for what you can upload are limitless. We’ve selected a few popular examples to get your creative juices flowing.
Dr. H. Morgan Scott - Science and Practice - How does the Science of Antibiot...John Blue
Science and Practice - How does the Science of Antibiotic Resistance and Use Get Applied in Veterinary and Farming Practices? - Dr. Eric Moore, Technical Director, Norbrook, Inc., Dr. H. Morgan Scott, Professor of Epidemiology, Texas A&M; Dr. Donna Carver, Extension Specialist, Poultry Veterinarian, North Carolina State University; Dr. Joel Nerem, Pipestone Veterinary Services, from the 2017 NIAA Antibiotic Symposium - Antibiotic Stewardship: Collaborative Strategy for Animal Agriculture and Human Health, October 31 - November 2, 2017, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2017-niaa-antibiotic-symposium-antibiotic-stewardship
EFFICACY IN REDUCING BACTERIAL CONTENT IN ORAL CAVITY BY CANNABINIODS IN ORAL...DrHeena tiwari
The document discusses a study that compared the efficacy of cannabinoids and popular oral care products (Oral-B and Colgate) in reducing bacterial content in dental plaque. Plaque samples were collected from 30 participants and exposed to cannabinoid toothpaste, Oral-B, and Colgate. Cannabinoids were found to significantly reduce bacterial colony counts compared to the other products. The results suggest cannabinoids may be more effective at controlling oral bacteria and could provide a personalized alternative to traditional oral care products.
Webinar: Defeating Superbugs: Hospitals on the Front Lines Modern Healthcare
About the Webinar: Defeating Superbugs: Hospitals on the Front Lines
http://www.modernhealthcare.com/article/20140917/INFO/309179926
Hospitals across the country are facing a grim reality in which some of the most deadly healthcare-associated infections they encounter are untreatable with first- or even second-line antibiotics. These “superbugs” affect at least 2 million Americans each year and lead to 23,000 deaths. And their threat is growing, public health officials warn. This editorial webinar and “Defeating Superbugs” white paper will explore the steps providers must take to ramp up surveillance efforts, promote appropriate antibiotic use and control outbreaks. Our panel of experts will share their organizations' experiences as well as proven strategies for success.
Registration for this webinar includes Modern Healthcare's “Defeating Superbugs” white paper, with proven tips and strategies for promoting appropriate antibiotic use, improving infection surveillance, identifying drug-resistant infections and dealing with outbreaks.
KEY TAKEAWAYS
- Best practices for effective antimicrobial stewardship
- Real-world examples of effective interventions, including universal rapid testing for drug-resistant MRSA
- Tips for engaging senior leadership
- Aggressive strategies for controlling outbreaks
PANELISTS
Lance Peterson
Director of the Clinical Microbiology and Infectious Disease Research Division
NorthShore University HealthSystem, Evanston, Ill.
Anurag Malani
Medical Director for the Infection Prevention and Antimicrobial Stewardship Programs
St. Joseph Mercy Hospital, Ann Arbor, Mich.
Robert Weinstein
Chief Medical Officer for Population Health
Chairman of the Department of Medicine, Cook County Health and Hospitals System; Professor, Rush University Medical Center, Chicago
MODERATOR
Maureen McKinney
Editorial Programs Manager
Modern Healthcare
Antibiotics in the management of chronic periodontitis.pptmalti19
This document summarizes evidence on the use of adjunctive antibiotics for chronic periodontitis. A systematic review of 25 studies found some additional benefits of antibiotics in deep pockets, including 0.2-0.6 mm more attachment gain and 0.2-0.8 mm more probing depth reduction. However, the clinical relevance is uncertain given limitations in defining chronic periodontitis and its microbiota. Overall, current studies have not conclusively established benefits of adjunctive antibiotics, so they cannot be routinely indicated as adjuncts for chronic periodontitis.
This corporate presentation discusses BELLUS Health's focus on developing drugs for rare diseases. Their lead product candidate, KIACTA, is in Phase 3 trials for AA amyloidosis, a rare and deadly kidney disease with no existing treatment. Positive results from a previous Phase 3 trial showed KIACTA slowed kidney function decline. If successful, KIACTA could achieve premium pricing compared to other orphan drugs. BELLUS is also developing treatments for other rare diseases including sHUS and AL amyloidosis through clinical trials and partnerships.
This document summarizes research on using a "BCG prime - DNA boost" vaccination strategy for tuberculosis. Key points:
- Mice vaccinated with BCG followed by a boost with DNA encoding the M. tuberculosis antigen α-crystallin had significantly reduced lung and spleen bacterial loads compared to BCG alone after airborne infection.
- The boosted mice also had less severe lung, liver and spleen pathology and granulomas.
- Protection lasted for at least 16 weeks and was associated with an increased proportion of the cytokines IL-12 and decreased IL-10 in the lungs.
- The results suggest boosting BCG with α-crystallin DNA enhances and prolongs protection against tuberculosis
The document discusses the human gut microbiota and its therapeutic applications. It provides details on the composition and functions of the gut microbiota, factors that influence it, methods for assessing its functions, and associated diseases. It also discusses probiotics, prebiotics, postbiotics, fecal microbiota transplantation, and the development of microbiome-based therapeutics to modulate the gut microbiota for therapeutic purposes.
Download Global cancer immunotherapy market outlook 2020KuicK Research
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Global cancer immunotherapy market outlook 2020KuicK Research
The document provides an overview of the global cancer immunotherapy market outlook for 2020. It discusses how cancer immunotherapies work by modulating the immune system to treat cancer. The market has seen significant growth with many approved and pipeline immunotherapies across classes like monoclonal antibodies, cytokines, vaccines, and immune checkpoint inhibitors. The market is expected to continue growing in coming years due to increased research and funding leading to new treatment modalities and biomarkers to expand the use of immunotherapies for additional cancer types.
Dr. Ananda Kumar Kondepati, M.D. and
Dr. Shalini D. Pasumarthi, M.D.
Canada, 2015
Clinical Research Program Supervisor:
Pr. Peivand Pirouzi, Ph.D., M.B.A., C.C.P.E.
This study developed antibiotic pellets containing rifampin and clindamycin to treat biofilms, which are implicated in chronic otitis media. The pellets released antibiotics for up to 21 days in tests, achieving drug levels high enough to eradicate biofilms in an in vitro model. Using modified-release antibiotic formulations in the middle ear may be a promising new therapy for persistent ear infections by targeting biofilms.
CHLA Pediatric Health Investment Opportunities_Sept 16Jessica Rousset
This document provides information on investment opportunities in pediatric health at a leading pediatric academic medical center. It summarizes the center's patient population and annual statistics, lists several interdisciplinary centers focused on critical pediatric health issues, describes the research institute including NIH funding and clinical trials, and provides information on the center for innovation and several startup companies with pediatric health technologies.
This document provides an overview of Canopus BioPharma Inc.'s drug development pipeline. It discusses treatments and research for conditions such as Ebola, cancer, immune disorders, infections, neurological disorders, cardiovascular disease, and Alzheimer's disease. Key points include positive in vitro test results for an Ebola treatment called CB-008, various oncology and immunomodulation drug candidates, and research into nutraceuticals for stress/anxiety, addiction therapy, and sarcopenia. It also describes benefits of antibodies derived from camel antibodies over conventional monoclonal antibodies for therapeutic applications.
Early phase drug development and the fda roadmap final version 2axE. Dennis Bashaw
This is the slide deck used in my webinar that was presented on 2/1/2018 on the FDA Predictive Toxicology Roadmap. It was presented at a webinar hosted by BioIVT in my private capacity and is not an official statement of FDA policy
Microbiome: The genes and genomes of the microbiota, as well as the products of the microbiota and the host environment” [the collective genomes of the micro-organisms in a particular environment. Although the composition of the gut microbiota varies between individuals, the community in each individual is relatively stable over time.
Targovax provides a summary of their company presentation on activating the immune system to fight cancer. They have two clinical programs, ONCOS oncolytic virus and TG neoantigen vaccine. ONCOS has ongoing clinical trials in mesothelioma, melanoma, ovarian and colorectal cancers. Early results show immune activation and clinical activity. Their focus is developing ONCOS as the lead product, with mesothelioma as the potential initial indication due to its orphan drug designation. Financially, Targovax has sufficient cash into the second half of 2019 to complete their planned clinical program.
The Evolution of Melaleuca Alternifolia Concentrate/98aliveSteven Hall
1) The document summarizes the evolution and development of Melaleuca Alternifolia Leaf Concentrate (98 Alive) by Professor Max Reynolds as an alternative anti-microbial agent.
2) Laboratory and clinical studies showed the concentrate was effective against various bacteria, fungi, viruses and had low toxicity. Specific studies demonstrated effectiveness against coronaviruses, herpes, influenza, and dengue fever.
3) A small clinical trial of HIV/AIDS patients found that after treatment with the concentrate for over a year, patients' viral loads decreased by an average of 83% and CD4 counts increased by an average of 168%, with patients returning to normal lifestyles.
The seminar is about this article: Containment of a Methicillin-resistant Staphylococcus aureus outbreak in a Neonatal Intensive Care Unit.
I described
Management of antibiotic resistance uploadAnimesh Gupta
This document discusses antibiotic resistance and its management. It defines antibiotic resistance as when microorganisms become resistant to drugs that previously treated infections from them. It outlines various mechanisms of antibiotic resistance in microorganisms and lists priority resistant bacteria. It also discusses superbugs and different strategies to manage antibiotic resistance like prudent antibiotic use, infection control, developing new drugs, and reducing agricultural overuse of antibiotics.
Similar to Kinnear Pharmaceuticals_BIO 2015_Final_Short (20)
1. CORPORATE OVERVIEW FOR BIO 2015
J U N E 2 0 1 5
P H A R M A C E U T I C A L S I N S P I R E D B Y T H E H U M A N I N N AT E I M M U N E S Y S T E M
1
2. Ceragenins are Innate Immune Modulators
Novel,proprietarysmallmoleculemimeticsofdefensins,keycomponentsoftheinnateimmunesystem
Proprietary, small molecule functional mimetics of defensins or cationic antimicrobial peptides (AMPs)
Ceragenins therapeutically modulate the innate immune system
Portfolio of >100 compounds that differentially exhibit immunomodulatory, anti-inflammatory,
antimicrobial, antiviral, anticancer, and osteoinduction activities
Subject of >40 peer reviewed scientific publications, $ millions of public and private investment, and
multiple >$10 million transactions in pharmaceuticals and animal health products
2
3. Kinnear Pharmaceuticals’ Emerging Portfolio
Building a portfoliothatleveragesceragenins’anti-inflammatoryandulcerationhealing andpreventionactivities
Program in vitro Efficacy in vivo Efficacy Preclinical Safety Phase 1
Oral Mucositis 2015-16* 2017*
Inflammatory Bowel Disease 2015-16* 2017*
Bone (Osteoinduction)
Cystic Fibrosis Inhaled Anti-infective
Multiple Myeloma
*The optimized portfolio strategy, after oral mucositis, will be determined by end of Q4 2015; actual timing depends upon capital availability.
Current base case assumes 2 – 3 programs move forward:
Oral mucositis is lead program with KIN-219 as lead candidate
IBD is second program with KIN-219 as lead candidate, leveraging oral toxicology and CMC investments made for oral mucositis
Undisclosed radiation countermeasure program under evaluation by NIH and DOD
Bone and cystic fibrosis programs move forward with non-dilutive, foundation or partner funding only
3
4. Mucositis is the Leading Radiation Oncology Toxicity
Oralmucositisisa serioussideeffectof headandneckcancertherapythatoftenstoponcologytreatment
Complication of several types of cancer therapy
◦ Radiation for head and neck cancers
◦ Conventional, cycled chemotherapy for solid tumors
◦ Hematopoietic stem cell transplantation (HSCT)
Painful and debilitating inflammation and ulceration
◦ Moderate to severe cases inhibit eating and drinking; can lead to death
◦ Can be dose limiting, requiring reduction or stoppage of cancer therapy
◦ Secondary bacterial or fungal infections, including a 4x septicemia risk
Significant pharmacoeconomic burden
◦ ~$21,800 (2012) incremental cost per head and neck patient1
◦ ~$33,000 (2012) incremental cost per 1-pt increase in HSCT patients2
Significant unmet clinical need
◦ Few and mostly ineffective prophylactics and therapies
◦ Options range from homeopathic, devices, to a single Rx for HSCT
Grade 1 (Mild)
Oral soreness, erythema
Grade 2 (Moderate)
Oral erythema, ulcers,
solid diet tolerated
Grade 3 (Severe)
Oral ulcers, liquid diet
only
Grade 4 (Life-threatening)
Parenteral or enteral
feeding only, intubation
Grade 0 (None)3
4
5. The Human Innate Immune System Plays a Key Role in
the Development of Oral Mucositis
Innateimmuneresponsemodulationduring initiationphaseisconsideredthebesttherapeuticstrategy
Radiation and chemotherapy induce an excessive
innate immune response in the targeted tissues,
producing a damaging inflammatory response
Ideal oral mucositis drug profile:
Reduces the innate inflammatory response
Provides broad-spectrum antimicrobial protection
Aids lesion healing or host repair processes
Acts prophylactically and therapeutically
Small molecule providing cost and stability advantage
Normal
Epithelium
Initiation Amplification Ulceration Healing
Damaged epithelium
increases risk of infection
Mucositis Phases
5
6. KIN-219 Reduced Severe Oral Mucositis >90%
Unsurpassed,“spectacular”performancebya non-peptideornon-polymersmallmoleculedrug candidate
>20% REDUCTION REQUIRED FOR DRUG VIABILITY
KIN-009 & KIN-219 BOTH EXCEEDED 90%
KIN-219 (LIGHT BLUE) PROVIDED THE STRONGEST
AND LONGEST LASTING REDUCTION
Data generated by Biomodels (Watertown, MA) in a translatable oral mucositis model
6
7. Next Study Will Evaluate Prophylaxis and Treatment
Studydesignincludesfractionatedradiationand2 treatmentarms;tobeconductedbyBiomodels(Watertown,MA)
KIN-219
KIN-219
KIN-219
KIN-219
7
8. KIN-219 Oral Rinse for Oral Mucositis
KinnearPharmaceutical’sleadprogramwithexpectedcompositionofmattercoveragebeyond2030
KIN-219 PROPERTIES SUPPORT DEVELOPMENT
~8 and 3 step, scalable synthetic pathways
Adequate solubility in water
Stable in solution and in biological environments
Demonstrates secondary antimicrobial activity
Low oral bioavailability expected
CERAGENINS DISPLAY ANTI-INFLAMMATORY,
ANTIMICROBIAL AND LESION HEALING ACTIVITIES
Ceragenins down regulate critical inflammatory markers:
◦ TNFα
◦ NF-kB
◦ IL-6
Ceragenins upregulate hyaluronan and CYR61/CCN1, key
factors in epithelial cell proliferation and migration as well
as tissue healing
CSA-13 showed in vivo efficacy for oral mucositis and IBD;
KIN-219 is a close analog of CSA-13
Ceragenins demonstrate broad-spectrum antimicrobial
activity, including multidrug resistant strains and biofilms
8
10. CSA-13 Reduced Severity of Colitis in an IBD model
Data generatedinaninvivocolitismodelatUCLA;currentlyplanning a followupstudyatCincinnatiChildren’sHospital
Figure 3:
(A) Experimental plan of chronic
TNBS colitis in mice. n=10 mice per
group. (B) H&E staining. CSA13
reduced TNBS colitis-mediated
mucosal transformation and round
cell infiltration in colons. (C)
Histology score. (D) CSA13 reduced
TNBS colitis-induced colonic
proinflammatory cytokine TNFa
expression. . (E) Mouse Raw264.7
macrophages were incubated with
LPS and CSA13 for 16 hours. CSA13
inhibited LPS-induced mouse TNFa
protein expression.
10
11. Ceragenins Upregulate Hyaluronan and CYR61/CCN1
Keydriversinepithelialcellproliferationandmigration,aswellastissuehealing,positivelyimpactedbyCSA-13
Figure 4:
(A) Human non-transformed colonic NCM460
epithelial cells incubated with CSA13 for 8
hours induced CYR61/CCN1 protein
expression. (B) Human intestinal
microvascular endothelial cells incubated
with CSA13, anti-CYR61 neutralizing antibody
(20mg/ml) and VEGF for 24 hours. CSA13
induced tube formation was blocked by anti-
CYR61 neutralizing antibody. (C) NCM460
cells were incubated with CSA13 and anti-
CYR61 antibody (20mg/ml, #NB100-356,
Novus Biologicals) for 72 hours. CSA13
induced cell proliferation was blocked by anti-
CYR61 neutralizing antibody. (D) Colonic
Cyr61/Ccn1 mRNA expression in mice was
increased in DSS colitis and was augmented
by intracolonic CSA13 administration.
D.
11
12. IBD Development Plan
Preliminarydevelopmentplanshowsexitpotentialin~3- 4 years,assuming KIN-219isleadcandidate
Opportunity Validation
•Confirmatory efficacy
•$85K + overhead
Preclinical Development
•Candidate screening for process R&D
•FIH enabling toxicology, if needed
•Modified release dose form development +
animal testing
•Clinical planning
•Regulatory interactions
• $300K + overhead
Phase 1a/1b Trial
•FIH clinical trials
•Human indication of activity
•Potential Breakthrough designation
•$2.8M + overhead
Phase 2a Trial
•~90 patients
•2 dose levels
•Human efficacy
•$7.5M + overhead
Phase 2b Trial
2015 2016 2017 2018 2019
12
13. Potential Anti-inflammatory Expansion Indications
BasedonsimilarclinicalpathophysiologytooralmucositisandIBD
Mucositis as a result of radiation oncology therapy and/or radiation + chemotherapy
◦ Oropharyngeal
◦ Proctitis
◦ Gastric mucositis
Post-radiation exposure gastric mucositis
◦ NIH and DOD priority countermeasure
◦ ‘Dirty bomb’ treatment for Strategic National Stockpile
◦ 4 May 2015 review of data with NIH and DOD for potential inclusion in free drug screening program
◦ Gateway to significant and expedited federal funding
13
14. Capital Requirements from May 2015 Forward
Marginal costs associatedwitha secondindicationlargelyattributabletodirect R&D expenses
Seeking a $6 million raise in Q4 2015 to fund preclinical development of oral mucositis and IBD
Will require a $7.5 million raise to fund Phase 1 studies in Q4 2016 (plan to conduct studies in
Australia; potential 43.5% tax credit not reflected in capital requirements)
Expense Category Opportunity Validation
(May 2015 – June 2016)
Preclinical
(July 2016 – Nov 2016)
Phase 1
(Dec 2016 – Dec 2017)
Phase 2a
(Jan 2018 – Dec 2018)
Oral mucositis R&D $1.8 M $1.7 M $3.0 M $3.3 M
IBD R&D $0.09 M $0.30 M $2.8 M $7.5 M
Pharma G&A $1.6 M $0.55 M $1.5 M $1.3 M
IP & License $0.85 M $0.06 M $0.24 M $0.22 M
Total by Phase $4.3 M $2.6 M $7.5 M $12 M
14
15. Oral Mucositis alone is a >$500 million Opportunity
KIN-219is3xmoreeffectiveintranslatableanimalefficacymodelsthanSoligenix’sSGX942
Oral mucositis market estimates:
◦ MuGard believes it can achieve sales of
$350 million by 2020
◦ RxKinetix believes the mucositis market
potential is in excess of $1 billion
IBD is a significantly larger market
opportunity than oral mucositis
Potential medical countermeasure
programs could provide non-dilutive R&D
capital with possible Strategic National
Stockpile sales
In total, Kinnear Pharmaceuticals
represents >>$100 million opportunity
15
16. Kinnear Pharmaceuticals Leadership Team
Successfultrackrecordof monetizing noveltechnologiesanddriving innovationagendas
•Progressive leadership roles at Procter & Gamble, Ventaira Pharmaceuticals and Battelle in R&D, technology
commercialization, and corporate strategy
Michael Triplett, PhD - Chief Executive Officer
•Former director of early stage drug R&D, liaison to venture capital funds, and leader of technical due diligence for
Procter & Gamble Pharmaceuticals
Bruce Halpryn, PhD - Chief Operating Officer
•KPMG, Borden Chemical, venture backed companies, and private equity experience
Ken Leachman - Chief Financial Officer
•VP of Empire Advisors where he is instrumental in fund operations, negotiations, and portfolio company
operations; formerly with Latham & Watkins LLP
David V. Richards, JD - VP, Corporate Development
16
17. Kinnear Pharmaceuticals Summary
•Ceragenins are small molecule mimetics of human antimicrobial peptides, innate immune modulators often called defensins,
that express anti-inflammatory, antimicrobial, anticancer and osteoinduction pharmacological activities
Development-stage pharmaceutical company leveraging the ceragenin small molecule platform
•Additional programs inflammatory bowel disease (IBD), cystic fibrosis, bone growth (osteoinduction), and multiple myeloma
Building a gastrointestinal anti-inflammatory pipeline with oral mucositis as the lead program and
inflammatory bowel a successor program utilizing the same active ingredient as oral mucositis
•The company was founded in 2015 as a successor to N8 Medical, which split into two entities, a medical device company
which retained the N8 Medical name and Kinnear Pharmaceuticals, each pursuing ceragenin applications.
Seeking a $6 million equity investment to advance the oral mucositis and inflammatory bowel
disease programs, supported by strong preclinical efficacy data, through preclinical completion
17
18. MICHAEL TRIPLETT, PH.D.
CHIEF EXECUTIVE OFFICER
614.360.3160
MTRIPLETT@KINNEARPHARMA.COM
BRUCE HALPRYN, PH.D.
CHIEF OPERATING OFFICER
513-659-4690
BHALPRYN@KINNEARPHARMA.COM
18
19. DISCLAIMER
Certain statements made in this presentation may include historical information and forward looking
actions that Kinnear Pharmaceuticals anticipates based on certain assumptions. These statements,
indicated by words such as “expect,” “anticipate,” “should,” etc., denote uncertainty in facts, figures
and outcomes. While Kinnear Pharmaceuticals believes that the expectations reflected in such
forward-looking statements are reasonable, it can give no assurance that such statements will prove to
be correct. Please contact Kinnear Pharmaceuticals for a full explanation of the risks associated with
an investment in Kinnear Pharmaceuticals.
The information provided in this presentation is being supplied to the best of the presenter’s
knowledge. You are not entitled to rely upon any information that is provided to you by Kinnear
Pharmaceuticals in this presentation. In deciding to enter into any transaction, you must rely upon
your own independent due diligence and investigations. Information presented in this presentation
does not constitute legal or financial advice, and you are encouraged to consult your professional
advisors regarding any such advice.
This presentation is copyright 2015 Kinnear Pharmaceuticals.
All Rights Reserved.
19